Compositions and Methods for Treating Pain with Wogonin

Abstract

The invention described herein relates to compositions and methods for treating pain with wogonin. In particular, described herein are compositions and methods for treating musculoskeletal pain and arthritis with wogonin.

1 - 30 . (canceled) 
     
     
         31 . A method for reducing or relieving pain in a patient, comprising locally administering a composition comprising wogonin or its derivatives thereof in a therapeutically effective amount of about 1 μM to about 500 μM to one or more sites of the patient having pain and reducing or relieving the pain. 
     
     
         32 . The method of  claim 31 , wherein the pain is selected from a musculoskeletal pain and arthritis pain. 
     
     
         33 . The method of  claim 32 , wherein the musculoskeletal pain stems from a sore muscle, a strained muscle, a bruised muscle, or a torn muscle. 
     
     
         34 . The method of  claim 32 , wherein the musculoskeletal pain stems from a sore tendon, a strained tendon, a bruised tendon, or a torn tendon. 
     
     
         35 . The method of  claim 31 , wherein the administration is selected from topical administration, transdermal administration, subcutaneous administration and local injection. 
     
     
         36 . The method of  claim 31 , wherein the administration is transdermal administration. 
     
     
         37 . The method of  claim 31 , wherein the wogonin is administered as an immediate release topical formulation, a delayed release topical formulation, a continuous release topical formulation, or an extended release topical formulation. 
     
     
         38 . The method of  claim 31 , wherein one or more additional anti-inflammatory drugs is administered before, after, or concurrently with the administration of wogonin. 
     
     
         39 . The method of  claim 31 , wherein the composition is in a form of a liquid, rub, foam, cream, solution, emulsion, gel, spray, wipes, a lotion, or a patch or combinations thereof. 
     
     
         40 . The method of  claim 39 , wherein the composition is a cream. 
     
     
         41 . The method of  claim 40 , wherein the cream comprises one or more transdermal penetration enhancers. 
     
     
         42 . The method of  claim 31 , wherein a perception of the pain by the patient is reduced by about 10% to about 100% after administration of the wogonin. 
     
     
         43 . A method for treating and promoting healing of an arthritic joint in a patient comprising administering a composition comprising wogonin or its derivatives thereof in a therapeutically effective amount of about 1 μM to about 500 μM locally to one or more arthritic joints of the patient, thereby treating and promoting the healing of the arthritic joint. 
     
     
         44 . The method of  claim 43 , wherein the administration is selected from topical administration, transdermal administration, subcutaneous administration and local injection. 
     
     
         45 . The method of  claim 43 , wherein an expression of a ceramide is increased, TGF-β1 is increased, MMP-13 is decreased, HtrA1 is decreased, NFκβ is decreased, and AGE is decreased within or proximally surrounding the arthritic joint, comprising cartilage and synovial fluid, compared to an arthritic joint not treated with wogonin. 
     
     
         46 . The method of  claim 45 , wherein the expression of cytokines HtrA1, MMP-13, NFκβ and AGE are reduced by at least 20% and TGF-β1, ceramide, and BBS 3 are elevated by at least 20% compared to an arthritic joint not treated with wogonin. 
     
     
         47 . The method of  claim 43 , wherein the therapeutically effective amount elicits an effect comprising one or more of: decreased cyst-like lesions (CLLs), a lower OARSI score, and inhibition of the primary cilia pathway of cartilage degradation. 
     
     
         48 . A topical pain composition comprising a concentration of wogonin or its derivatives thereof of about 1 μM to about 500 μM and a cosmetically or dermatologically acceptable carrier. 
     
     
         49 . The composition of  claim 48 , wherein the composition is in a form of a liquid, rub, foam, cream, solution, emulsion, gel, spray, wipes, a lotion, or a patch or combinations thereof. 
     
     
         50 . The composition of  claim 49 , comprising one or more of: dimethyl sulfone, polyethylene glycol or polypropylene glycol, peppermint oil, coconut oil, and shea butter. 
     
     
         51 . The composition of  claim 50 , wherein the composition comprises:
 a) about 0.03% to about 5% dimethyl sulfone;   b) about 1% to about 8% polyethylene glycol or polypropylene glycol;   c) about 1% to about 7% peppermint oil;   d) about 0.3% to about 50% shea butter;   e) about 0.14% to about 26% coconut oil; and   f) about 15% to about 85% water.